000			02261 a2200661 4500
005			20250513190635.0
264		0	_c19990909
008			199909s 0 0 eng d
022			_a0891-6934
024	7		_a10.3109/08916939908994767 _2doi
040			_aNLM _beng _cNLM
100	1		_aNomura, S
245	0	0	_aGenetic analysis of HLA- and HPA-typing in idiopathic (autoimmune) thrombocytopenic purpura patients treated with cepharanthin. _h[electronic resource]
260			_bAutoimmunity _c1999
300			_a99-105 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAlkaloids _xpharmacology
650	0	4	_aAnti-Inflammatory Agents _xtherapeutic use
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xpharmacology
650	0	4	_aAntigens, Human Platelet _xanalysis
650	0	4	_aAutoantigens _xgenetics
650	0	4	_aAutoimmune Diseases _xdrug therapy
650	0	4	_aBenzylisoquinolines
650	0	4	_aBlood Platelets _ximmunology
650	0	4	_aCombined Modality Therapy
650	0	4	_aDrug Resistance _xgenetics
650	0	4	_aEndocytosis _xdrug effects
650	0	4	_aFemale
650	0	4	_aGenetic Predisposition to Disease
650	0	4	_aGenotype
650	0	4	_aHLA Antigens _xanalysis
650	0	4	_aHLA-DQ Antigens _xanalysis
650	0	4	_aHLA-DQ beta-Chains
650	0	4	_aHLA-DR Antigens _xanalysis
650	0	4	_aHLA-DRB1 Chains
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPolymerase Chain Reaction
650	0	4	_aPolymorphism, Restriction Fragment Length
650	0	4	_aPolymorphism, Single-Stranded Conformational
650	0	4	_aPrednisolone _xtherapeutic use
650	0	4	_aPurpura, Thrombocytopenic, Idiopathic _xdrug therapy
650	0	4	_aSplenectomy
650	0	4	_aTreatment Outcome
700	1		_aMatsuzaki, T
700	1		_aYamaoka, M
700	1		_aOzaki, Y
700	1		_aNagahama, M
700	1		_aYoshimura, C
700	1		_aKagawa, H
700	1		_aNakayama, S
700	1		_aFukuhara, S
773	0		_tAutoimmunity _gvol. 30 _gno. 2 _gp. 99-105
856	4	0	_uhttps://doi.org/10.3109/08916939908994767 _zAvailable from publisher's website
999			_c10393498 _d10393498